[…]Requires a least one randomized controlled trial (RCT) as part of the evidence B. Requires well-controlled clinical studies, but no RCT C. Requires clinical experience of respected authorities Other frameworks make finer distinctions among different levels of evidence (e.g., Oxford Centre for EBM Levels of Evidence), but the thrust of each is the same. The āgold standardā for credibility is met by randomized, double-blind, placebo-controlled trials, with multi-site studies being preferred to single-site studies. The unique advantage of randomization is that it enables researchers to evaluate whether the intervention (or product) itself, as opposed to other factors, causes any observed […]
[…]on addressing questions patients frequently ask their physicians about its use, and based on up-to-date science, suggest ways to improve physician-patient discussions about cannabis and apply them to a clinical setting. Presenter: Itai Danovitch, MD Dr. Danovitch is President of the California Society of Addiction Medicine, and Chair for the Department of Psychiatry and Director of Addiction Psychiatry at Cedars Sinai Medical Center. His research interests have focused on substance use disorders, particularly marijuana, as well as the integration of medical and mental health services. Educational Objectives Upon completion of this program, participants should be able to: Answer patientsā questions […]
[…]diabetic. All too often CSAM physicians see their patients work towards a false goal of medication-free abstinence that is reinforced by societal prejudice and a system of reimbursement that pays for detoxification but not maintenance. When patients risk relapse back to illicit opiates, they jeopardize relationships with the ones they love. Patients who relapse back to opiate addiction endanger their jobs, threaten their quality of life, and most importantly, imperil their health. The risks of relapse are especially dangerous amidst the current HIV and hepatitis C epidemics Methadone maintenance is a treatment for opiate addiction that is safe, efficacious, and […]
[…]of Medical Specialties (ABMS). Additionally, the locator lists the specialty information for each member (as supplied by the member) and information about each member’s current positions. Only current CSAM members are listed in the locator. If you are a physician, addiction medicine professional, or a medical student and would like to be included in the physician locator, the first step is to join ASAM/CSAMĀ here. If you would like to be removed from the listing, please notify us here. Consumer […]
[…]all of which CSAM supports: AB 2651 (Bains) Support AB 2651 would create, upon appropriation by the Legislature, the Licensed Alcohol Drug Counselor Board within the Department of Consumer Affairs. The bill would require the board to establish regulations and standards for the licensure of alcohol drug counselors, as specified. The bill would authorize the board to collaborate with the Department of Health Care Access and Information regarding behavioral health professions, review sunrise review applications for emerging behavioral health license and certification programs and refer complaints regarding behavioral health workers to appropriate agencies, as specified. AB 2115 (Haney) Support Under current law, […]
[…]of Preventive Medicine, Addiction Medicine Subspecialty Board Exam in 2024. Our other Wednesday Pre-conference workshops will focus on psychedelics, the state of the art in opioid use disorder treatment, addressing our child and adolescent populations, while MERF (Medical Education Research Foundation) will offer its popular MI (Motivational Interviewing) workshop on Wednesday as well. And last but not the least, MERF scholars and conference attendees will have an opportunity to share their research and other projects through multiple Poster Sessions over the course of conference. In short, whether you are a late, mid or early career physician, a physician in training, […]
[…]pleased to announce that we are hard at work developing our small group case discussions, a time-honored CSAM tradition. Our attendees consistently tell us that this is one of the many things that set CSAM conferences apart, as these discussions enhance both learning and community building. We have been asked over the years why the case discussions donāt include outcomes and I had the opportunity to discuss this with Dr. Steve Eickelberg, who is one of our cherished long-term CSAM members and who has written so many of the cases that you have been challenged by over the years. Hereās […]
[…]prevention, recognition and treatment approaches that acknowledge addiction as a youth-onset condition. We are committed to: The CSAM Youth and Prevention Committee is unwavering in its dedication to improving the prevention and recovery landscape, ensuring a brighter and more resilient future for our youth and society. Committee on Youth and Prevention Roster Committee on Membership & Communications The Committee on Membership & Communications is responsible for recruitment of new members into CSAM and promoting active participation among the membership. In addition, the Committee is responsible for all of CSAM’s regular publications such as the newsletter, email broadcasts, and the CSAM […]
[…]over the last 15 years-that this view of cannabinoid action on brain reward processes and reward-related behaviors is untenable. This paper reviews those data, and concludes that cannabinoids act on brain reward processes and reward-related behaviors in strikingly similar fashion to other addictive drugs. Pistis, M., Muntoni, A. L., Pillolla, G., Gessa, G. L. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological studyEur J Neurosci. 2002 Jun;15(11):1795-802. Abstract The nucleus accumbens (NAc) represents a critical site for the rewarding properties of diverse classes of drugs of abuse. Glutamatergic afferents to the […]
